首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   311102篇
  免费   15373篇
  国内免费   1134篇
耳鼻咽喉   4029篇
儿科学   9263篇
妇产科学   8054篇
基础医学   45334篇
口腔科学   9071篇
临床医学   21198篇
内科学   68653篇
皮肤病学   8999篇
神经病学   25546篇
特种医学   8021篇
外国民族医学   47篇
外科学   36693篇
综合类   2659篇
现状与发展   1篇
一般理论   62篇
预防医学   32527篇
眼科学   7473篇
药学   23789篇
  6篇
中国医学   1618篇
肿瘤学   14566篇
  2023年   1627篇
  2022年   2315篇
  2021年   6597篇
  2020年   3726篇
  2019年   6247篇
  2018年   8862篇
  2017年   5801篇
  2016年   5875篇
  2015年   6742篇
  2014年   8492篇
  2013年   12255篇
  2012年   18836篇
  2011年   19527篇
  2010年   10697篇
  2009年   8790篇
  2008年   15916篇
  2007年   16783篇
  2006年   16131篇
  2005年   15622篇
  2004年   14398篇
  2003年   13444篇
  2002年   12950篇
  2001年   9304篇
  2000年   9818篇
  1999年   8066篇
  1998年   2199篇
  1997年   1605篇
  1996年   1458篇
  1992年   4257篇
  1991年   3982篇
  1990年   3840篇
  1989年   3396篇
  1988年   3196篇
  1987年   2981篇
  1986年   2950篇
  1985年   2742篇
  1984年   2032篇
  1983年   1727篇
  1979年   2136篇
  1978年   1395篇
  1975年   1475篇
  1974年   1909篇
  1973年   1866篇
  1972年   1762篇
  1971年   1642篇
  1970年   1636篇
  1969年   1678篇
  1968年   1668篇
  1967年   1484篇
  1966年   1331篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
2.
3.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
4.
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to...  相似文献   
5.
6.
7.
Breast pseudoaneurysms after a core needle biopsy are a rare complication with a low incidence. However, it is important to be aware of the possibility of complications that require treatment.  相似文献   
8.
9.
10.
Introduction: In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement.

Areas covered: This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) – PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED).

Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH. Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1-adrenoceptors and should be used as the first option. Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, tadalafil improves sexual function.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号